Cyteir Therapeutics

About:

Cyteir is developing the next generation of synthetic lethal therapies to treat cancer.

Website: http://cyteir.com/

Twitter/X: cyteir_tx

Top Investors: RA Capital Management, National Institutes of Health, Novo Holdings, Venrock, Janus Henderson Investors

Description:

Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer. The company is using its expertise in DNA damage response biology to advance a pipeline of novel drug candidates that selectively target key cancer vulnerabilities. Cyteir’s wholly owned lead compound, CYT-0851, is a potent and selective, oral investigational drug that was designed to inhibit RAD51-mediated homologous recombination and the repair of double-strand DNA breaks.